Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 12/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | RECQL | P46063 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847832 | 0.86 | TERT (0.72) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL4649946 | 0.83 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL29374601 | 0.81 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL419316 | 0.81 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6613777 | 0.81 | TERT (0.76) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6617302 | 0.81 | TERT (0.76) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL21852713 | 0.80 | TERT (0.97) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL35318 | 0.78 | TERT (1.00) | TERTALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL6804531 | 0.77 | TERT (0.81) | TERTALDH1A1CYP3A4MAPTHPGD | |
| 7,8-Dihydroxyflavone SCHEMBL29577498 | 0.76 | TERT (0.89) | TERTALDH1A1CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | claimed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | claimed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | claimed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | claimed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2930/4885ALDH1A1 1116/4885CYP3A4 1228/4885 |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2908/4885ALDH1A1 1274/4885CYP3A4 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.